Mineralys Therapeutics

MLYS45

$12.45arrow_drop_down7.10%-$0.95

MLYS45

$12.45

arrow_drop_down7.10%-$0.95

Performance History

Key Stats
Open	$13.51
Prev. Close	$14.92
EPS	-2.76
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	12.90	15.32
52 Week Range	5.85	16.90

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Mineralys Therapeutics (MLYS)

Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing innovative therapies for the treatment of various diseases. The company's mission is to improve the lives of patients by bringing new, effective treatments to market. With a strong pipeline of novel drug candidates, Mineralys Therapeutics is well-positioned for future growth and success. The company's stock price history has shown steady growth, reflecting investor confidence in the potential of its drug portfolio.

In recent news, Mineralys Therapeutics announced positive results from a Phase 2 clinical trial for its lead drug candidate, MLY-101. The trial demonstrated significant efficacy and safety in treating patients with a rare genetic disorder. This milestone achievement has generated excitement among investors and has contributed to the company's positive market performance.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Jon Congleton
Headquarters: Radnor
Employees: 12
Exchange: NASDAQ

Keep an eye on Mineralys Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Mineralys Therapeutics's (MLYS) price per share?

The current price per share for Mineralys Therapeutics (MLYS) is $12.45. The stock has seen a price change of -$0.95 recently, indicating a -7.1% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Mineralys Therapeutics (MLYS)?

For Mineralys Therapeutics (MLYS), the 52-week high is $16.9, which is 35.78% from the current price. The 52-week low is $5.85, the current price is 112.82% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Mineralys Therapeutics (MLYS) a growth stock?

Mineralys Therapeutics (MLYS) has shown an average price growth of -3.13% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Mineralys Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Mineralys Therapeutics (MLYS) stock price performance year to date (YTD)?

As of the latest data, Mineralys Therapeutics (MLYS) has a year-to-date price change of 43.43%. Over the past month, the stock has experienced a price change of -8.39%. Over the last three months, the change has been 5.24%. Over the past six months, the figure is -3.71%.

help

Is Mineralys Therapeutics (MLYS) a profitable company?

Mineralys Therapeutics (MLYS) has a net income of -$71.9M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$84.66M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Mineralys Therapeutics (MLYS)?

Mineralys Therapeutics (MLYS) has a market capitalization of $659.13M. The average daily trading volume is 12.77, indicating the stock's liquidity and investor engagement.

News

HYPERTENSION

LORUNDROSTAT

CLINICAL TRIAL

MINERALYS THERAPEUTICS

Sep 25, 2024

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

MINERALYS THERAPEUTICS

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!

DIRECTORS AND OFFICERS

HEALTH

Jun 14, 2024

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

CALENDAR OF EVENTS

CONFERENCE CALLS/ WEBCASTS

Mar 13, 2024

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024